Disclosure
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - 'Joint Venture Partnership Between Pleiades Therapeutics And Vista Pharmaceuticals Ltd'
Filed with BSE ·
6ix hasn’t read this filing yet.
View original source (BSE India)Vista Pharmaceuticals Ltd. on 6ix
Story so far
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Announcement under Regulation 30 (LODR)-Newspaper Publication
- Outcome Of Circular Resolution Passed By Board Of Directors Of The Company By Circulation On July 16, 2025 Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Earlier from Vista Pharmaceuticals
- Vista Pharmaceuticals Ltd. Press Release Jan 13 2026
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Vista Pharmaceuticals Ltd. Press Release Nov 04 2025
- Board Meeting Intimation for 1. Unaudited Financial Results For The Quarter Ended 30.09.2025.2. Limited Review Report For Quarter Ended 30.09.2025.3. Any Other Business With The Permission Of The Chair.
- Vista Pharmaceuticals Ltd. Press Release Oct 14 2025
Later from Vista Pharmaceuticals
- Board Meeting Intimation for 1. Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2025.2. Limited Review Report Quarter And Nine Months 31.12.2025.3. Any Other Business With The Permission Of The Chair.
- Update on board meeting
- Vista Pharmaceuticals Ltd. Press Release Feb 05 2026
- Results For The Quarter Ended 31.12.2025
- Board Meeting Outcome for Un Audited Financial Results For The Quarter Ended 31.12.2025
Follow Vista Pharmaceuticals into a list and get an email when it puts out news.
Follow Vista Pharmaceuticals